Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Pharmos (PARS) -- Ignore unavailable to you. Want to Upgrade?

To: ADEL 7 who wrote (220)	11/18/1998 2:24:00 PM
From: Ariella	Read Replies (3) \| Respond to of 1386

Adel -- I believe we have an excellent management team, but they are subject to the pressures of the market. The logic of the TBI drug was so obvious to me the first time I heard about it, I didn't really need to be "educated" as to its importance, just educated as to the medical realities like blood-brain barrier, ICP, etc. So it has taken a little wind out of my sails this week to realize that the company had to educate even neurologists initially (who only wanted to talk about stroke application for HU-211) that the TBI market was really big. Of course, management must continue this education project on Wall Street as well. None of the above reflects poorly on PARS management itself. Value is something that changes on Wall Street (by fad sometimes even or by rumor -- I made 8 points in MALL since Friday because of rumors), by the realities that large funds look for $1 billion cap stocks in which to trade. It is certainly not management's fault that the Street cannot see the "sexiness" in their eye drugs and business model. In a sense, we're not "in style" in this respect. That accounts for part of the lackluster stock price movement. Short of blaming management for having gone into the "wrong" business, I don't see how this can be their fault. This management is bright, honest, hard-working -- all one can ask for in a management team. The place where I'd like to make changes is on Wall Street, which seems more and more often to reward only the big pharmaceuticals. -Ariella